BioNTech SE BNTX
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -11.11% | -86.92% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -11.11% | -86.92% | |||
| Cost of Revenue | 35.05% | -76.30% | |||
| Gross Profit | -81.69% | -92.24% | |||
| SG&A Expenses | 30.39% | -30.44% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 826.64% | -89.12% | |||
| Total Operating Expenses | 19.10% | -33.62% | |||
| Operating Income | -24.34% | -126.19% | |||
| Income Before Tax | -50.26% | -151.09% | |||
| Income Tax Expenses | -4.08% | -146.89% | |||
| Earnings from Continuing Operations | -53.40% | -75.28% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -53.40% | -75.28% | |||
| EBIT | -24.34% | -126.19% | |||
| EBITDA | -4.03% | -110.73% | |||
| EPS Basic | -53.37% | -68.85% | |||
| Normalized Basic EPS | -36.13% | -166.25% | |||
| EPS Diluted | -53.37% | -68.85% | |||
| Normalized Diluted EPS | -36.13% | -166.25% | |||
| Average Basic Shares Outstanding | 0.02% | 3.81% | |||
| Average Diluted Shares Outstanding | 0.02% | 3.81% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||